Insmed (NASDAQ: INSM) reported Q4 EPS of ($1.28), $0.12 worse than the analyst estimate of ($1.16). Revenue for the quarter came in at $83.69 million versus the consensus estimate of $82.37 million.

Balance Sheet, Financial Guidance, and Planned Investments

As of December 31, 2023, Insmed had cash, cash equivalents, and marketable securities totaling $780.4 million.
Insmed is reiterating its sales guidance for full-year 2024 global ARIKAYCE revenues in the range of $340 million to $360 million, representing 15% year-over-year growth at the midpoint compared to 2023.
Insmed continues to anticipate that over 80% of total annual expenditures will be on its mid- to late-stage and commercial programs (ARIKAYCE, brensocatib, and TPIP), and that less than 20% of overall spend will be on its early-stage research programs, reflecting the Company\'s historical approach to spending.

For earnings history and earnings-related data on Insmed (INSM) click here.